333 related articles for article (PubMed ID: 24775564)
1. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
[TBL] [Abstract][Full Text] [Related]
2. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism.
Cook KM; Hilton ST; Mecinovic J; Motherwell WB; Figg WD; Schofield CJ
J Biol Chem; 2009 Sep; 284(39):26831-8. PubMed ID: 19589782
[TBL] [Abstract][Full Text] [Related]
3. Up-Regulation of ENO1 by HIF-1α in Retinal Pigment Epithelial Cells after Hypoxic Challenge Is Not Involved in the Regulation of VEGF Secretion.
Zheng F; Jang WC; Fung FK; Lo AC; Wong IY
PLoS One; 2016; 11(2):e0147961. PubMed ID: 26882120
[TBL] [Abstract][Full Text] [Related]
4. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma.
Viziteu E; Grandmougin C; Goldschmidt H; Seckinger A; Hose D; Klein B; Moreaux J
Br J Cancer; 2016 Mar; 114(5):519-23. PubMed ID: 26867162
[TBL] [Abstract][Full Text] [Related]
5. Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.
Goey AK; Chau CH; Sissung TM; Cook KM; Venzon DJ; Castro A; Ransom TR; Henrich CJ; McKee TC; McMahon JB; Grkovic T; Cadelis MM; Copp BR; Gustafson KR; Figg WD
J Nat Prod; 2016 May; 79(5):1267-75. PubMed ID: 27140429
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.
Harris EM; Strope JD; Beedie SL; Huang PA; Goey AKL; Cook KM; Schofield CJ; Chau CH; Cadelis MM; Copp BR; Gustafson KR; Figg WD
Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029505
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
8. [Development of a novel screening assay for inhibitors targeting HIF-1alpha and P300 interaction].
Lai FF; Niu F; Yang HZ; Zhou WQ; Chen XG
Yao Xue Xue Bao; 2014 Jun; 49(6):849-53. PubMed ID: 25212031
[TBL] [Abstract][Full Text] [Related]
9. Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300.
Na YR; Han KC; Park H; Yang EG
Biochem Biophys Res Commun; 2013 May; 434(4):879-84. PubMed ID: 23618863
[TBL] [Abstract][Full Text] [Related]
10. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
[TBL] [Abstract][Full Text] [Related]
11. AGR2-induced glucose metabolism facilitated the progression of endometrial carcinoma via enhancing the MUC1/HIF-1α pathway.
Gong W; Ekmu B; Wang X; Lu Y; Wan L
Hum Cell; 2020 Jul; 33(3):790-800. PubMed ID: 32304027
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
13. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.
Gray MJ; Zhang J; Ellis LM; Semenza GL; Evans DB; Watowich SS; Gallick GE
Oncogene; 2005 Apr; 24(19):3110-20. PubMed ID: 15735682
[TBL] [Abstract][Full Text] [Related]
14. Roles of p300 and cyclic adenosine monophosphate response element binding protein in high glucose-induced hypoxia-inducible factor 1α inactivation under hypoxic conditions.
Ding L; Yang M; Zhao T; Lv G
J Diabetes Investig; 2017 May; 8(3):277-285. PubMed ID: 27808477
[TBL] [Abstract][Full Text] [Related]
15. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Sonawane V; Rathos MJ; Kumar S; Joshi KS
BMC Cancer; 2011 Aug; 11():338. PubMed ID: 21819554
[TBL] [Abstract][Full Text] [Related]
16. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
17. Visualization of hypoxia-inducible factor 1α-p300 interactions in live cells by fluorescence resonance energy transfer.
Kim SY; Lee MJ; Na YR; Kim SY; Yang EG
J Cell Biochem; 2014 Feb; 115(2):271-80. PubMed ID: 23966271
[TBL] [Abstract][Full Text] [Related]
18. Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics.
Deep G; Kumar R; Nambiar DK; Jain AK; Ramteke AM; Serkova NJ; Agarwal C; Agarwal R
Mol Carcinog; 2017 Mar; 56(3):833-848. PubMed ID: 27533043
[TBL] [Abstract][Full Text] [Related]
19. MFTZ-1 reduces constitutive and inducible HIF-1α accumulation and VEGF secretion independent of its topoisomerase II inhibition.
Dai M; Miao ZH; Ren X; Tong LJ; Yang N; Li T; Lin LP; Shen YM; Ding J
J Cell Mol Med; 2010 Sep; 14(9):2281-91. PubMed ID: 19538463
[TBL] [Abstract][Full Text] [Related]
20. HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.
Kessler J; Hahnel A; Wichmann H; Rot S; Kappler M; Bache M; Vordermark D
BMC Cancer; 2010 Nov; 10():605. PubMed ID: 21050481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
